Si cierra, no se guardará su personalización salvo que haya añadido el artículo a su carrito de la compra o a favoritos.
Pulse OK para cerrar la herramienta MILLIPLEX® MAP o Cancelar para volver a su selección.
Elija paneles personalizables y kits premezclos - O - MAPmates™ de señalización celular
Diseñe y calcule el precio de sus kits MILLIPLEX® MAP.
Paneles personalizados y kits premezclados
Nuestra amplia cartera de productos consta de paneles multiplex que le permiten elegir, dentro del panel, los analitos que mejor se ajustan a sus requisitos. En una pestaña distinta puede elegir el formato de citocina premezclada o un kit single plex.
Kits de señalización celular y MAPmates™
Elija los kits preparados para poder explorar las vías o los procesos enteros. O diseñe sus propios kits eligiendo single plex MAPmates™ según las directrices proporcionadas.
No deben combinarse los siguientes MAPmates™: -MAPmates™ que requieren un tampón de ensayo diferente. -Pares MAPmate™ fosfoespecíficos y totales, por ejemplo, GSK3β y GSK3β (Ser 9). -MAPmates™ con panTyr y específicos de sitio; por ejemplo, receptor del fosfo-EGF y fosfo-STAT1 (Tyr701). -Más de 1 fosfo-MAPmate™ para una sola diana (Akt, STAT3). -La GAPDH y la β-tubulina no pueden combinarse con kits o MAPmates™ que contengan panTyr.
.
Número de referencia
Descripción para pedidos
Cant./Env.
Lista
Este artículo se ha añadido a favoritos.
Seleccione una especie, un tipo de panel, un kit o un tipo de muestra
Para empezar a diseñar su kit MILLIPLEX® MAP, seleccione una especie, un tipo de panel o un kit de interés.
Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Catalogue Number
Ordering Description
Qty/Pack
List
Este artículo se ha añadido a favoritos.
Especie
Tipo de panel
Kit seleccionado
Cant.
Número de referencia
Descripción para pedidos
Cant./Env.
Precio de catálogo
96-Well Plate
Cant.
Número de referencia
Descripción para pedidos
Cant./Env.
Precio de catálogo
Añadir más reactivos (Se necesita tampón y un kit de detección para usar con MAPmates)
Cant.
Número de referencia
Descripción para pedidos
Cant./Env.
Precio de catálogo
48-602MAG
Buffer Detection Kit for Magnetic Beads
1 Kit
Opción para ahorrar espacio Los clientes que adquieran múltiples kits pueden optar por ahorrar espacio de almacenamiento retirando el embalaje del kit y recibiendo los componentes de sus ensayos multiplex en bolsas de plástico para un almacenamiento más compacto.
Este artículo se ha añadido a favoritos.
El producto se ha añadido a su carrito
Ahora puede personalizar otro kit, elegir un kit premezclado, tramitarlo o cerrar la herramienta de pedidos.
Mutations in either retinoid isomerase (RPE65) or lecithin-retinol acyltransferase (LRAT) lead to Leber congenital amaurosis (LCA). By using the Lrat(-/-) mouse model, previous studies have shown that the rapid cone degeneration in LCA was caused by endoplasmic reticulum (ER) stress induced by S-opsin aggregation. The purpose of this study is to examine the efficacy of an ER chemical chaperone, tauroursodeoxycholic acid (TUDCA), in preserving cones in the Lrat(-/-) model.Lrat(-/-) mice were systemically administered with TUDCA and vehicle (0.15 M NaHCO(3)) every 3 days from P9 to P28. Cone cell survival was determined by counting cone cells on flat-mounted retinas. The expression and subcellular localization of cone-specific proteins were analyzed by western blotting and immunohistochemistry, respectively.TUDCA treatment reduced ER stress and apoptosis in Lrat(-/-) retina. It significantly slowed down cone degeneration in Lrat(-/-) mice, resulting in a ∼3-fold increase in cone density in the ventral and central retina as compared with the vehicle-treated mice at P28. Furthermore, TUDCA promoted the degradation of cone membrane-associated proteins by enhancing the ER-associated protein degradation pathway.Systemic injection of TUDCA is effective in reducing ER stress, preventing apoptosis, and preserving cones in Lrat(-/-) mice. TUDCA has the potential to lead to the development of a new class of therapeutic drugs for treating LCA.
Retinal pigmented epithelium derived from human induced pluripotent stem (iPS) cells (iPS-RPE) may be a source of cells for transplantation. For this reason, it is essential to determine the functional competence of iPS-RPE. One key role of the RPE is uptake and processing of retinoids via the visual cycle. The purpose of this study is to investigate the expression of visual cycle proteins and the functional ability of the visual cycle in iPS-RPE.iPS-RPE was derived from human iPS cells. Immunocytochemistry, RT-PCR, and Western blot analysis were used to detect expression of RPE genes lecithin-retinol acyl transferase (LRAT), RPE65, cellular retinaldehyde-binding protein (CRALBP), and pigment epithelium-derived factor (PEDF). All-trans retinol was delivered to cultured cells or whole cell homogenate to assess the ability of the iPS-RPE to process retinoids.Cultured iPS-RPE expresses visual cycle genes LRAT, CRALBP, and RPE65. After incubation with all-trans retinol, iPS-RPE synthesized up to 2942 ± 551 pmol/mg protein all-trans retinyl esters. Inhibition of LRAT with N-ethylmaleimide (NEM) prevented retinyl ester synthesis. Significantly, after incubation with all-trans retinol, iPS-RPE released 188 ± 88 pmol/mg protein 11-cis retinaldehyde into the culture media.iPS-RPE develops classic RPE characteristics and maintains expression of visual cycle proteins. The results of this study confirm that iPS-RPE possesses the machinery to process retinoids for support of visual pigment regeneration. Inhibition of all-trans retinyl ester accumulation by NEM confirms LRAT is active in iPS-RPE. Finally, the detection of 11-cis retinaldehyde in the culture medium demonstrates the cells' ability to process retinoids through the visual cycle. This study demonstrates expression of key visual cycle machinery and complete visual cycle activity in iPS-RPE.
In the present study we have used adenovirus-mediated gene transfer of apoA-I (apolipoprotein A-I) mutants in apoA-I-/- mice to investigate how structural mutations in apoA-I affect the biogenesis and the plasma levels of HDL (high-density lipoprotein). The natural mutants apoA-I(R151C)Paris, apoA-I(R160L)Oslo and the bioengineered mutant apoA-I(R149A) were secreted efficiently from cells in culture. Their capacity to activate LCAT (lecithin:cholesterol acyltransferase) in vitro was greatly reduced, and their ability to promote ABCA1 (ATP-binding cassette transporter A1)-mediated cholesterol efflux was similar to that of WT (wild-type) apoA-I. Gene transfer of the three mutants in apoA-I-/- mice generated aberrant HDL phenotypes. The total plasma cholesterol of mice expressing the apoA-I(R160L)Oslo, apoA-I(R149A) and apoA-I(R151C)Paris mutants was reduced by 78, 59 and 61% and the apoA-I levels were reduced by 68, 64 and 55% respectively, as compared with mice expressing the WT apoA-I. The CE (cholesteryl ester)/TC (total cholesterol) ratio of HDL was decreased and the apoA-I was distributed in the HDL3 region. apoA-I(R160L)Oslo and apoA-I(R149A) promoted the formation of prebeta1 and alpha4-HDL subpopulations and gave a mixture of discoidal and spherical particles. apoA-I(R151C)Paris generated subpopulations of different sizes that migrate between prebeta and alpha-HDL and formed mostly spherical and a few discoidal particles. Simultaneous treatment of mice with adenovirus expressing any of the three mutants and human LCAT normalized plasma apoA-I, HDL cholesterol levels and the CE/TC ratio. It also led to the formation of spherical HDL particles consisting mostly of alpha-HDL subpopulations of larger size. The correction of the aberrant HDL phenotypes by treatment with LCAT suggests a potential therapeutic intervention for HDL abnormalities that result from specific mutations in apoA-I.